Evidence map›Paper›PMID 28219903›Full record

ArticleEMBO reports2017

MYC-driven inhibition of the glutamate-cysteine ligase promotes glutathione depletion in liver cancer.

Brittany Anderton, Roman Camarda, Sanjeev Balakrishnan, Asha Balakrishnan, Rebecca A Kohnz, Lionel Lim, Kimberley J Evason, Olga Momcilovic, Klaus Kruttwig, Qiang Huang and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EMBO reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 77 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Ferroptosis and its relationship with cancer.Frontiers in cell and developmental biology · 2024
    Review
  18. Covalent Targeting of Glutamate Cysteine Ligase to Inhibit Glutathione Synthesis.Chembiochem : a European journal of chemical biology · 2023
    Article
  19. miRNA-Based Technologies in Cancer Therapy.Journal of personalized medicine · 2023
    Review
  20. Emerging role of miRNAs in the regulation of ferroptosis.Frontiers in molecular biosciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Brittany AndertonDepartment of Cell and Tissue Biology, University of California, San Francisco, San Francisco, CA, USA.
Roman CamardaDepartment of Cell and Tissue Biology, University of California, San Francisco, San Francisco, CA, USA.
Sanjeev BalakrishnanDepartment of Cell and Tissue Biology, University of California, San Francisco, San Francisco, CA, USA.
Asha BalakrishnanDepartment of Cell and Tissue Biology, University of California, San Francisco, San Francisco, CA, USA.
Rebecca A KohnzDepartment of Nutritional Sciences and Toxicology, University of California, Berkeley, CA, USA.
Lionel LimDepartment of Cell and Tissue Biology, University of California, San Francisco, San Francisco, CA, USA.
Kimberley J EvasonDepartment of Pathology and Huntsman Cancer Institute, University of Utah, Salt Lake, UT, USA.
Olga MomcilovicDepartment of Cell and Tissue Biology, University of California, San Francisco, San Francisco, CA, USA.
Klaus KruttwigDepartment of Cell and Tissue Biology, University of California, San Francisco, San Francisco, CA, USA.
Qiang HuangKey Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China.
Guowang XuKey Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, China.
Daniel K NomuraDepartment of Nutritional Sciences and Toxicology, University of California, Berkeley, CA, USA.
Andrei GogaDepartment of Cell and Tissue Biology, University of California, San Francisco, San Francisco, CA, USA Andrei.goga@ucsf.edu.ORCID 0000-0001-9127-0986
University of California, San Francisco · USDalian Institute of Chemical Physics · CNUniversity of California, Berkeley · USUniversity of Utah · US

Funding

UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026
$30.7M
Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRUMMEL, MATTHEW F · 2003 to 2019
$21.8M
DIABETES, ENDOCRINOLOGY &METABOLISM TRAINING PROGRAMT32DK007418 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI EDWARD C HSIAO · 1986 to 2026
$14.3M
MOLECULAR AND CELLULAR IMMUNOLOGYT32AI007334 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CYSTER, JASON G · 1988 to 2023
$11.0M
Transcellular epigenetic regulation by ex-small RNA in C. elegantU19CA179512 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BLELLOCH, ROBERT · 2013 to 2017
$7.4M
PREDOCTORAL TRAINING IN BIOMEDICAL SCIENCEST32GM008568 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANSEL, KARL MARK · 1995 to 2019
$6.3M
In Vivo Metabolic Catastrophe Is Induced By Acute Oncogene Inhibition (PQ #22)R01CA170447 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOGA, ANDREI · 2012 to 2015
$2.4M
Targeting the MYC Oncogene with CDK InhibitorsR01CA136717 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOGA, ANDREI · 2010 to 2014
$1.8M
Annotating the Role of Dysregulated Inositol Phosphate Metabolism in Malignant CaR01CA172667 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI NOMURA, DANIEL · 2013 to 2017
$1.7M
Mechanisms and modifiers of beta-catenin-induced hepatic tumorigenesisK08CA172288 · NCI · UNIVERSITY OF UTAH · PI EVASON, KIMBERLEY JANE · 2013 to 2017
$754k
Investigating Fatty Acid Oxidation in Primary and Metastatic MYC-Overexpressing Triple-Negative Breast CancerF99CA212488 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CAMARDA, ROMAN · 2016 to 2017
$72k
NCI NIH HHS F99 CA212488NCI NIH HHS K08 CA172288NCI NIH HHS R01 CA136717NCI NIH HHS R01 CA170447NCI NIH HHS R01 CA172667NCI NIH HHS U19 CA179512NIAID NIH HHS T32 AI007334NIDDK NIH HHS P30 DK026743NIDDK NIH HHS P30 DK063720NIDDK NIH HHS T32 DK007418NIGMS NIH HHS T32 GM008568
6 · The paper itself

Abstract

How MYC reprograms metabolism in primary tumors remains poorly understood. Using integrated gene expression and metabolite profiling, we identify six pathways that are coordinately deregulated in primary MYC-driven liver tumors: glutathione metabolism; glycine, serine, and threonine metabolism; aminoacyl-tRNA biosynthesis; cysteine and methionine metabolism; ABC transporters; and mineral absorption. We then focus our attention on glutathione (GSH) and glutathione disulfide (GSSG), as they are markedly decreased in MYC-driven tumors. We find that fewer glutamine-derived carbons are incorporated into GSH in tumor tissue relative to non-tumor tissue. Expression of GCLC, the rate-limiting enzyme of GSH synthesis, is attenuated by the MYC-induced microRNA miR-18a. Inhibition of miR-18a

Indexed as

AnimalsCell Line, TumorCluster AnalysisDisease Models, AnimalGene Expression ProfilingGene Expression Regulation, NeoplasticGlutamate-Cysteine LigaseGlutamineGlutathioneHumansLiver NeoplasmsMetabolic Networks and PathwaysMetabolomeMetabolomicsMiceMice, TransgenicGCLC protein, humanGlutamate-Cysteine LigaseGlutamineGlutathioneMicroRNAsMIRN18 microRNA, humanProto-Oncogene Proteins c-myccancerglutathionemetabolismmiRNAMYC

Identifiers

PMID28219903
PMCPMC5376764
OpenAlexW2590751720

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.